As the Affordable Care Act continues to negatively impact insurers in Massachusetts, sometimes causing major financial hits, they're taking specific steps to regain financial stability.
State Medicaid programs spent $1.33 billion on hepatitis C treatments through the third quarter of last year, according to an analysis of federal data.
Hepatitis C is an expensive health condition that only gets worse if treatment is delayed or postponed--and a new study published in the American Journal of Gastroenterology suggests that a lack of insurance is the "only barrier" facing those unable to obtain treatment.
Although Aetna reported increased fourth quarter profits and Humana said its profits were lower than expected, both insurers have favorable outlooks for 2015--largely because of agreements they've reached with hepatitis c drug maker Gilead.
Insurers are adopting more cost-sharing measures, especially coinsurance, to shift the costs of expensive specialty drugs onto consumers who purchase plans sold on health insurance exchanges, according to a new analysis from Avalere Health.
To help defray the high costs of certain treatments and prescription drugs, like hepatitis C drug Sovaldi, insurers are figuring out different ways to cover the drugs and services by limiting who can have access to them, reported Kaiser Health News.
Medicaid insurers are struggling to pay for pricey drugs, leading some to request states to increase payments so they can run their plans. Meanwhile, some states are deciding restrict the expensive medications.
As the health insurance and pharma industries clash over the cost of hepatitis C drugs, a new report finds the high-priced meds will drive up Medicare Part D spending by about $2.9 billion to $5.8 billion next year.
Given the recent surge in pricey prescription drugs, lawmakers are calling for Medicare to offer rebates and negotiate prices to reap significant savings, according to a report released Wednesday by advocacy groups the Medicare Rights Center and Social Security Works.
Comparative effectiveness research (CER), which helps payers determine plan coverage options based on the effectiveness of certain treatments, could improve the entire healthcare industry, according to Applied Clinical Trials.